http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0026813-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03721e344a72026d125291e6c56c1be6 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-3808 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 |
filingDate | 1980-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ddd9d67b74339305eae9121d441e314 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06873fcfdd0c5c23eb31ef1d88f8c894 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c51832186f0cf03b775433cf33d9074 |
publicationDate | 1981-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-0026813-A2 |
titleOfInvention | (N-phosphonoacetyl-L-aspartato) (1,2 diaminocyclohexane) platinum (II) and the sodium, potassium or lithium salts thereof, their preparation and pharmaceutical compositions containing them |
abstract | <CHEM>n where X is Na<+>, K<+>, Li<+> or H. n<??>(N-phosphonacetyl-L-aspartato) (1,2-diaminocyclohexane)platinum(II) or alkali metal salt thereof has shown antitumor activity in animals such as activity against murine leukemia L1210. Additionally, this agent is used against B-16 and Colon 38 tumors and also Ehrlich ascites tumor. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added hydroxyurea (HU) (1,000-1,500 mg/kg of body weight). n<??>In binary treatment with cis-dichlorodiamineplatinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1 : 10 in mg/kg of body weight. n<??>As to the variations in the formula on the left hand side of the formula, it may be varied as monodentate, such as cisplatin containing a single amine group proceeding from the ring, or bidentate, such as the present compound. The saturated cyclo ring may be C4 or C5-C7 in addition to the present cyclohexane. n<??>The present platinum compound may be prepared by reacting the known L-aspartic acid, N-(phosphonacetyl-) disodium salt (PALA; NSC-224 131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC-239 851). This compound N-phosphonacetyl-L-aspartato (1,2-diaminocyclohexane)platinum(II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds. For example, the compound denoted Pt-268 may be combined in a dual regimen with cyclophosphamide (CY), hydroxyurea (HU), and cisplatin. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5657470-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0281412-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0284197-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4886894-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4882447-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0130482-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0281412-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-604299-B2 |
priorityDate | 1979-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 839.